Insulet’s Omnipod 5 automated insulin delivery (AID) system is now being sold in five more countries: Italy, Denmark, Finland, Norway, and Sweden.

The Omnipod 5 AID is compatible with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 continuous glucose monitors (CGMs). It’s indicated for type 1 diabetes patients that are aged two years and older. According to Insulet, Omnipod 5 is the first, only tubeless AID system integrated with both leading CGM sensor brands.

The company also touted that Omnipod is the most popular insulin pump for new users in Europe and the number one prescribed AID system in the U.S. It’s also the first tubeless, waterproof AID system with proactive glucose control designed for ease of use, Insulet said.

Omnipod 5 rolled out in the UK and the Netherlands in June 2024. First introduced in the U.S. in 2022, real-world evidence has shown lower A1c and improved time in range, with low time in hypoglycemia. Also in June 2024, Insulet launched Omnipod 5 with the Dexcom G7 CGM.

“We are excited to bring our flagship Omnipod 5 AID System to more people across Europe,” said Patrick Crannell, Insulet’s senior VP and international general manager. “Following our successful launches of Omnipod 5 in the U.K., Germany, Netherlands, and France, today’s announcement marks another significant step forward to help improve the lives of people with diabetes around the world.”

Last month, a jury verdict returned in favor of Insulet concerning misappropriation of trade secrets by rival insulin pump maker EOFlow. Insulet was awarded a total of $452 in damages from EOFlow.